摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trifluoro-methanesulfonic acid 2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl ester | 548466-05-3

中文名称
——
中文别名
——
英文名称
trifluoro-methanesulfonic acid 2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl ester
英文别名
trifluoromethanesulfonic acid 2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl ester;1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl trifluoromethanesulfonate;1-methyl-3-trifluoromethyl-5-trifluoromethylsulphonyloxypyrazole;[2-methyl-5-(trifluoromethyl)pyrazol-3-yl] trifluoromethanesulfonate
trifluoro-methanesulfonic acid 2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl ester化学式
CAS
548466-05-3
化学式
C6H4F6N2O3S
mdl
——
分子量
298.166
InChiKey
NIBHGLGKFPQEGC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    274.2±40.0 °C(Predicted)
  • 密度:
    1.75±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    69.6
  • 氢给体数:
    0
  • 氢受体数:
    10

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 7-AZAINDOLE INHIBITORS OF CRAC
    申请人:Hoffmann-La Roche Inc.
    公开号:US20130158049A1
    公开(公告)日:2013-06-20
    Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.
    公开了公式(I)的化合物: 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病,通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
  • DIAZAINDOLE INHIBITORS OF CRAC
    申请人:Hoffmann-La Roche Inc.
    公开号:US20130158040A1
    公开(公告)日:2013-06-20
    Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.
    公开了公式(I)的化合物: 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病,通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
  • 4-AZAINDOLE INHIBITORS OF CRAC
    申请人:Hoffmann-La Roche Inc.
    公开号:US20130158066A1
    公开(公告)日:2013-06-20
    Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.
    公开了公式(I)的化合物: 用于治疗与IL-2抑制有关的自身免疫和炎症性疾病,通过调节钙释放激活钙(CRAC)通道。还公开了制造和使用这些化合物用于治疗与CRAC通道相关的疾病的方法。
  • Herbicidal method
    申请人:——
    公开号:US20030181334A1
    公开(公告)日:2003-09-25
    The invention relates to a method for the control of weeds (i.e. undesired vegetation) at a locus, which method comprises applying thereto a herbicidally effective amount of at least one compound which is a 3,5-dicyanophenoxy derivative of formula (I): 1 wherein A is as defined in the description; to novel 3,5-dicyanophenoxy derivatives, to new herbicidal compositions containing them, and to processes and intermediates for their preparation.
    该发明涉及一种用于控制杂草(即不受欢迎的植被)的方法,该方法包括向其施加至少一种化合物的除草有效量,所述化合物是公式(I)的3,5-二氰基苯氧衍生物:其中A如描述中定义;以及新的3,5-二氰基苯氧衍生物、含有它们的新除草组合物,以及用于它们制备的过程和中间体。
  • Discovery of 7-azaindole derivatives as potent Orai inhibitors showing efficacy in a preclinical model of asthma
    作者:Cristina Esteve、Jacob González、Sílvia Gual、Laura Vidal、Soledad Alzina、Sonia Sentellas、Irene Jover、Raquel Horrillo、Jorge De Alba、Montserrat Miralpeix、Gema Tarrasón、Bernat Vidal
    DOI:10.1016/j.bmcl.2015.01.063
    日期:2015.3
    Synthesis and SAR of a series of 7-azaindoles as Orai channel inhibitors showing good potency inhibiting IL-2 production in Jurkat cells is described. Compound 14d displaying best pharmacokinetic properties was further characterized in a model of allergen induced asthma showing inhibition in the number of eosinophils in BALF. High lipophilicity remains as one of the main challenges for this class of compounds. (C) 2015 Elsevier Ltd. All rights reserved.
查看更多